abstract |
ABSTRACT OF THE DISCLOSURE Derivatives of kanamycin A and B have been prepared which possess substantially improved antibacterial activity. Two examples of such agents are 1-[L-(-)-.delta.-amino-.alpha.-hydroxyvaleryl]-kanamycin A [IVa, BB-K23] and 1-[L-(-)-.beta.-amino-.alpha.-hydroxypropionyl]-kanamycin B [IVa, BB-K122]. |